

## **PRESS RELEASE – REGULATED INFORMATION**

### **Information on the total number of voting rights and shares**

**Liège (Belgium), 5 April 2022, 9h00 (CEST) – regulated information** – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Hyloris Pharmaceuticals SA/NV publishes the following information following the issue of 967.742 new shares on 5 April 2022 in the context of the completion of a capital increase through a private placement via an accelerated bookbuild offering (see the press release of 31 March 2022):

- Share capital: 134.001,87 EUR
- Total number of securities carrying voting rights: 26.800.374 (all ordinary shares)
- Total number of voting rights (= denominator): 26.800.374 (all relating to ordinary shares)
- Number of rights to subscribe securities carrying voting rights not yet issued:
  - 400,000 “ESOP Warrants” issued (in principle) on 27 November 2020, entitling their holders to subscribe for a total number of 400.000 securities carrying voting rights (all ordinary shares)
  - 333,000 “ESOP Warrants” issued on 31 December 2019, entitling their holders to subscribe for a total number of 333,000 securities carrying voting rights (all ordinary shares)
  - 300,000 “Transaction Warrants” issued on 12 May 2017, entitling their holders to subscribe for a total number of 1,200,000 securities carrying voting rights (all ordinary shares)
- In accordance with article 18 of the Law of 2 May 2007 on the disclosure of large shareholdings, the Company has set additional notification thresholds of 3% and 7,5%.

#### **For more information, contact:**

Hyloris Pharmaceuticals, Investors and Media

[investorrelations@hyloris.com](mailto:investorrelations@hyloris.com)

#### **About Hyloris Pharmaceuticals**

Hyloris is a specialty biopharma company focused on innovating, reinventing, and optimising existing medications to address important healthcare needs and deliver relevant improvements for patients, healthcare professionals and payors. Hyloris has built a broad, patented portfolio of 14 reformulated and repurposed value-added medicines that have the potential to offer significant advantages over available alternatives. Outside of its core strategic focus, the Company also has 4 high barrier generic products in development and registration phase. Two products are currently in initial phases of commercialisation with partners: Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV,

a non-opioid post-operative pain treatment. The Company's development strategy primarily focuses on the FDA's 505(b)2 regulatory pathway, which is specifically designed for pharmaceuticals for which safety and efficacy of the molecule have already been established. This pathway can reduce the clinical burden required to bring a product to market, and significantly shorten the development timelines and reduce costs and risks. Hyloris is based in Liège, Belgium. For more information, visit [www.hyloris.com](http://www.hyloris.com) and follow-us on [LinkedIn](#).